Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-15

Clinical Trial Update: Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 pediatric dose-finding study of linagliptin for type 2 diabetes completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Linagliptin (linagliptin)
  • Tradjenta (Linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2016-09-15